REFERENCES
- L. Aabakken, B. Olaussen, P. Mowinckel, and M. Osnes. (1992). Gastro-duodenal lesions associated with two different piroxicam formulations. An endoscopic evaluation. Scand. J. Gastroenterol. 27:1049–1054.
- L. Alvarez, A. Concheiro, J. L. Gómez-Amoza, C. Souto, and R. Martínez-Pacheco. (2002). Effect of microcrystalline cellulose grade and process variables on pellets prepared by extrusion–spheronization. Drug Dev. Ind. Pharm. 28:451–456.
- M. E. Aulton. (1990). Pharmaceutics: the Science of dosage form design (Vol. 1, 2 ed.) London: Churchill Livingstone.
- H. Bando, and J. W. McGinity. (2006). Relationship between drug dissolution and leaching of plasticizer for pellets coated with an aqueous Eudragit® S100:L100 dispersion. Int. J. Pharm. 323:11–17.
- F. Bashaiwoldu, B. Abraham, and J. M. N. Podczeck. (2004). The application of non-contact laser profilometry to the determination of permanent structural change induced by compaction of pellets II. Pellets dried by different techniques. Eur. J. Pharm. Sci. 22:55–61.
- R. Chopra, F. Podczeck, J. M. Newton, and G. Alderborn. (2002). The influence of pellet shape and film coating on the filling of pellets hard shell capsules. Eur. J. Pharm. Biopharm. 53:327–333.
- A. Debunne, C. Vervaet, D. Mangelings, and J. Remon. (2004). Compaction of enteric-coated pellets: Influence of formulation and process parameters on tablet properties and in vivo evaluation. Eur. J. Pharm. Sci. 22:305–314.
- L. Hu, Y. Liu, X. Tang, and Q. Zhan. (2006). Preparation and in vitro/in vivo evaluation of sustained-release metformin hydrochloride pellets. Eur. J. Pharm. Biopharm. 64:185–192.
- N. Huyghebaert, A. Vermeire, P. Rottiers, E. Remaut, and J. P. Remon. (2005). Development of an enteric-coated, layered multi-particulate formulation for ileal delivery of viable recombinant Lactococcus lactis. Eur. J. Pharm. Biopharm. 61:134–141.
- A. Y. Lin, and L. Larry. (2001). Augsburger. AAPS Pharm. Sci. 3 (2):1–12.
- S. Muatlik, A. N. Usha, M. S. Reddy, A. K. Ranjith, and S. Pandey. (2007). Improved bioavailability of aceclofenac from spherical agglomerates: Development, in vitro and preclinical studies. Pak. J. Pharm. Sci. 20 (3):218–226.
- S. Mutalik, P. Anju, K. Manoj, and A. N. Usha. (2008). Enhancement of dissolution rate and bioavailability of aceclofenac: A chitosan-based solvent change approach. Int. J. Pharm. 350 (1-2):279–290.
- A. Pareek, A. S. Chandanwale, J. Oak, U. K. Jain, and S. Kapoor. (2006). Efficacy and safety of aceclofenac in the treatment of osteoarthritis: a randomized double-blind comparative clinical trial versus diclofenac—an indian experience. Curr. Med. Res. Opin. 22 (5):977–988.
- M. Paulsson, and S. K. Singh. (1999). Colloidal and thermal characteristics of concentrated dispersions of polymethacrylate-based latices for aqueous enteric coating. J. Pharm. Sci. 88 (4):406–411.
- N. U. Rahman, and K. H. Yuen. (2005). Eudragit NE40-drug mixed coating system for controlling drug release of core pellets. Drug Dev. Ind. Pharm. 31:339–347.
- E. C. Rodriguez, J. J. Torrado, I. Nikoakakis, S. Torrado, J. L. Lastres, and S. Malamataris. (2001). Micromeritic and packing properties of diclofenac pellets and effets of some formulation varibles. Drug. Dev. Ind. Pharm. 27 (8):847–855.
- H. N. Shivakumar, S. Sarasija, and B. G. Desai. (2006). Design and evaluation of pH sensitive multi-particulate systems for chronotherapeutic delivery of diltiazem hydrochloride. Indian J. Pharm. Sci. 68 (6):781–787.
- P. Sriamornsak, J. Nunthanid, M. Luangtana-anan, and S. Puttipipatkhachorn. (2007). Alginate-based pellets prepared by extrusion/spheronization: A preliminary study on the effect of additive in granulating liquid. Eur. J. Pharm. Biopharm. 67:227–235.
- W. Zheng, and J. W. McGinity. (2003). Influence of eudragit NE 30 d blended with eudragit_ l 30 D-55 on the release of phenylpropanolamine hydrochloride from coated pellets. Drug Dev. Ind. Pharm. 29 (3):357–366.